Practice guidelines for the early detection of cervical cancer in Korea: Korean society of Gynecologic Oncology and the Korean society for Cytopathology 2012 edition

Journal of Gynecologic Oncology

Volumn 24, Issue 2, 2013, Pages 186-195

  Lee, Jae Kwan ^a   Hong, Jin Hwa ^a   Kang, Sokbom ^b   Kim, Dae Yeon ^c   Kim, Byoung Gie ^d   Kim, Sung Hoon ^e   Kim, Yong Man ^c   Kim, Jae Weon ^f   Kim, Jae Hoon ^g   Kim, Tae Jin ^h   Kim, Hyun Jung ⁱ   Kim, Hye Sun ^h   Ryu, Hee Sug ^j   Song, Jae Yun ^k   Ahn, Hyeong Sik ⁱ   Yoo, Chong Woo ^b   Yoon, Hye Kyoung ^l   Lee, Keun Ho ^m   Lee, Ahwon ^m   Lee, Yonghee ^j   Lee, In Ho ^h   Lee, Jeong Won ^d   Lee, Taek Sang ⁿ   Lim, Myong Cheol ^b   Chang, Suk Joon ^j   Chung, Hyun Hoon ^f   Ju, Woong ^o   Joo, Hee Jae ^j   Hur, Soo Young ^m   Hong, Sung Ran ^h   Nam, Joo Hyun ^c   more..

^a Korea University College of Medicine   (South Korea)

^b National Cancer Center   (South Korea)

^c University of Ulsan College of Medicine   (South Korea)

^d Sungkyunkwan University School of Medicine   (South Korea)

^e Yonsei University College of Medicine   (South Korea)

^f Seoul National University College of Medicine   (South Korea)

^g Yonsei University College of Medicine   (South Korea)

^h Kwandong University College of Medicine   (South Korea)

ⁱ Korea University   (South Korea)

^j Ajou University Medical CentSuwon   (South Korea)

^k College of Medicine   (South Korea)

^l Inje University College of Medicine   (South Korea)

^m The Catholic University of Korea College of Medicine   (South Korea)

ⁿ Seoul National University Boramae Hospital   (South Korea)

^o Ewha Womans University School of Medicine   (South Korea)

more..

Author keywords

Atypical glandular cells; Atypical squamous cells; Cervical cancer; Human papillomavirus; Screening; Squamous intraepithelial lesion

Indexed keywords

VIRUS DNA;

ABLATION THERAPY; CANCER DIAGNOSIS; CANCER SCREENING; COLPOSCOPY; CONSENSUS; CRYOTHERAPY; EARLY DIAGNOSIS; ENDOMETRIUM BIOPSY; EVIDENCE BASED PRACTICE; FALSE POSITIVE RESULT; FOLLOW UP; HEALTH CARE QUALITY; HUMAN; HUMAN PAPILLOMAVIRUS DNA TEST; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; HYSTERECTOMY; KOREA; NONHUMAN; PRACTICE GUIDELINE; PREGNANT WOMAN; REVIEW; SCREENING TEST; SEXUAL BEHAVIOR; SQUAMOUS CELL; UTERINE CERVIX CANCER; UTERINE CERVIX CYTOLOGY;

EID: 84880740277     PISSN: 20050380     EISSN: 20050399     Source Type: Journal    
DOI: 10.3802/jgo.2013.24.2.186     Document Type: Review

References (93)

1. Schiffman M, Castle PE. The promise of global cervical-cancer prevention. N Engl J Med 2005;353:2101-2104.
2. Wright TC Jr, Massad LS, Dunton CJ, Spitzer M, Wilkinson EJ, Solomon D. 2006 Consensus guidelines for the manage-ment of women with abnormal cervical cancer screening tests. Am J Obstet Gynecol 2007;197:340-345.
3. Partridge EE, Abu-Rustum NR, Campos SM, Fahey PJ, Farmer M, Garcia RL, et al. Cervical cancer screening. J Natl Compr Canc Netw 2010;8:1358-1386.
4. Moyer VA; U.S. Preventive Services Task Force. Screening for cervical cancer: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med 2012;156: 880-891.
5. Institute for Clinical System Improvement. Initial manage-ment of abnormal cervical cytology (Pap test) and HPV test in adult and adolescent females. Bloomington, MN: Institute for Clinical System Improvement; 2013 [cited 2013 Mar 19]. Available from: https://www.icsi.org/_asset/hks01y/AbPap-Interact0910.pdf.
6. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin 2011;61:69-90.
7. Lee YH, Choi KS, Lee HY, Jun JK. Current status of the National Cancer Screening Program for cervical cancer in Korea, 2009. J Gynecol Oncol 2012;23:16-21.
8. Guyatt GH, Oxman AD, Kunz R, Vist GE, Falck-ytter Y, Schunemann HJ. What is "quality of evidence" and why is it important to clinicians? BMJ 2008;336:995-998.
9. Schunemann HJ, Oxman AD, Brozek J, Glasziou P, Jaeschke R, Vist GE, et al. Grading quality of evidence and strength of recommendations for diagnostic tests and strategies. BMJ 2008;336:1106-1110.
10. Insinga RP, Glass AG, Rush BB. Diagnoses and outcomes in cervical caner screening: a population-based study. Am J Obstet Gynecol 2004;191:105-113.
11. Sigurdsson K. Cervical cancer: cytological cervical screening in Iceland and implications of HPV vaccines. Cytopathology 2010;21:213-222.
12. Sigurdsson K, Sigvaldason H. Is it rational to start population-based cervical cancer screening at or soon after age 20? Analysis of time trends in preinvasive and invasive diseases. Eur J Cancer 2007;43:769-774.
13. Peto J, Gilham C, Deacon J, Taylor C, Evans C, Binns W, et al. Cervical HPV infection and neoplasia in a large population-based prospective study: the Manchester cohort. Br J Cancer 2004;91:942-953.
14. Woodman CB, Collins S, Winter H, Bailey A, Ellis J, Prior P, et al. Natural history of cervical human papillomavirus infection in young women: a longitudinal cohort study. Lancet 2001;357:1831-1836.
15. Sasieni P, Castanon A, Cuzick J. Effectiveness of cervical screening with age: population based case-control study of prospectively recorded data. BMJ 2009;339:b2968.
16. Taylor S, Kuhn L, Dupree W, Denny L, De Souza M, Wright TCJr. Direct comparison of liquid-based and conventional cytology in a South African screening trial. Int J Cancer 2006;118:957-962.
17. Coste J, Cochand-Priollet B, Cremoux P, Le Gales C, Cartier I, Molinie V, et al. Cross sectional study of conventional cervical smear, monolayer cytology, and human papillo-mavirus DNA testing for cervical cancer screening. BMJ 2003;326:733.
18. Cochand-priollet B, Le Gales C, de Cremoux P, Molinie V, Sastre-Garau X, Vacher-Lavenu MC et al. Cost-effecti-veness of monolayers and human papillomavirus testing compared to that of conventional Papanicolaou smears for cervical cancer screening: protocol of the study of the French Society of Clinical Cytology. Diagn Cytopathol 2001;24:412-420.
19. Ronco G, Cuzick J, Pierotti P, Cariaggi MP, Dalla Palma P, Naldoni C, et al. Accuracy of liquid based versus conven-tional cytology: overall results of new technologies for cervical cancer screening: randomized controlled trial. BMJ 2007; 335:28.
20. Siebers AG, Klinkhamer PJ, Grefte JM, Massuger LF, Vedder JE, Beijers-Broos A, et al. Comparison of liquid-based cyto-logy with conventional cytology for detection of cervical cancer precursors: a randomized controlled trial. JAMA 2009;302:1757-1764.
21. Baldauf JJ, Dreyfus M, Lehmann M, Ritter J, Philippe E. Cervical cancer screening with cervicography and cytology. Eur J Obstet Gynecol Reprod Biol 1995;58:33-39.
22. Autier P, Coibion M, De Sutter P, Wayemberg M. Cytology alone versus cytology and cervicography for cervical and cervicography for cervical cancer screening: a randomized study. European Society for Oncological Research. Obstet Gynecol 1999;93:353-358.
23. Kim YT, Kim JW, Kim SH, Kim YR, Kim JH, Yoon BS, et al. Clinical usefulness of cervicogram as a primary screening test for cervical neoplasia. Yonsei Med J 2005;46:213-220.
24. Moscicki AB, Schiffman M, Kjaer S, Villa LL. Updating the natural history of HPV and anogenital cancer. Chapter 5. Vaccine 2006;24(3):S42-S51.
25. Ronco G, Segnan N, Giorgi-Rossi P, Zappa M, Casadei GP, Carozzi F, et al. Human papillomavirus testing and liquid-based cytology: results at recruitment from the new technologies for cervical cancer randomized controlled trial. J Natl Cancer Inst 2006;98:765-774.
26. Ronco G, Giorgi-Rossi P, Carozzi F, Confortini M, Dalla Palma P, Del Mistro A, et al. Efficacy of human papillo-mavirus testing for the detection of invasive cervical cancers and cervical intraepithelial neoplasia: a rando- mised controlled trial. Lancet Oncol 2010;11:249-257.
27. Ronco G, Giorgi-Rossi P, Carozzi F, Confortini M, Dalla Palma P, Del Mistro A, et al. Results at recruitment from a randomized controlled trial comparing human papillomavirus testing alone with conventional cytology as the primary cervical cancer screening test. J Natl Cancer Inst 2008;100:492-501.
28. Ronco G, Cuzick J, Segnan N, Brezzi S, Carozzi F, Folicaldi S, et al. HPV triage for low grade (L-SIL) cytology is appropriate for women over 35 in mass cervical cancer screening using liquid based cytology. European Journal of Cancer 2007; 43: 476-480.
29. Ronco G, Brezzi S, Carozzi F, Dalla Palma P, Giorgi-Rossi P, Minucci D, et al. The New Technologies for Cervical Cancer Screening randomised controlled trial: an overview of results during the first phase of recruitment. Gynecol Oncol 2007;107:S230-S232.
30. Laurila P, Hakama M, et al. Screening with a primary 30. Kotaniemi-Talonen L, Anttila A, Malila N, Tarkkanen J, human papillomavirus test does not increase detection of cervical cancer and intraepithelial neoplasia 3. Eur J Cancer 2008;44:565-571.
31. Tarkkanen J, Laurila P, et al. Age-specific evaluation of 31. Leinonen M, Nieminen P, Kotaniemi-Talonen L, Malila N, primary human papillomavirus screening vs conventional cytology in a randomized setting. J Natl Cancer Inst 2009;101:1612-1623.
32. Anttila A, Kotaniemi-Talonen L, Leinonen M, Hakama M, Laurila P, Tarkkanen J, et al. Rate of cervical cancer, severe intraepithelial neoplasia, and adenocarcinoma in situ in primary HPV DNA screening with cytology triage: randomised study within organised screening programme. BMJ 2010;340:c1804.
33. Anttila A, Hakama M, Kotaniemi-Talonen L, Nieminen P. Alternative technologies in cervical cancer screening: a randomised evaluation trial. BMC Public Health 2006;6:252.
34. Kotaniemi-Talonen L, Nieminen P, Anttila A, Hakama M. Routine cervical screening with primary HPV testing and cytology triage protocol in a randomised setting. Br J Cancer 2005;93:862-867.
35. Boeke AJ, Bulk S, et al. Human papillomavirus DNA testing 35. Bulkmans NW, Berkhof J, Rozendaal L, van Kemenade FJ, for the detection of cervical intraepithelial neoplasia grade 3 and cancer: 5-year follow-up of a randomised controlled implementation trial. Lancet 2007;370:1764-1772.
36. Bulkmans NW, Rozendaal L, Snijders PJ, Voorhorst FJ, Boeke AJ, Zandwijken GR, et al. POBASCAM, a population- based randomized controlled trial for implementation of high-risk HPV testing in cervical screening: design, methods and baseline data of 44,102 women. Int J Cancer 2004;110:94-101.
37. Naucler P, Ryd W, Tornberg S, Strand A, Wadell G, Elfgren K, et al. Human papillomavirus and Papanicolaou tests to screen for cervical cancer. N Engl J Med 2007;357:1589-1597.
38. Naucler P, Ryd W, Tornberg S, Strand A, Wadell G, Elfgren K, et al. Efficacy of HPV DNA testing with cytology triage and/or repeat HPV DNA testing in primary cervical cancer screening. J Natl Cancer Inst 2009;101:88-99.
39. Elfgren K, Rylander E, Radberg T, Strander B, Strand A, Paajanen K, et al. Colposcopic and histopathologic evaluation of women participating in population-based screening for human papillomavirus deoxyribonucleic acid persistence. Am J Obstet Gynecol 2005;193:650-657.
40. Kitchener HC, Almonte M, Thomson C, Wheeler P, Sargent A, Stoykova B, et al. HPV testing in combination with liquid-based cytology in primary cervical screening (ARTISTIC): a randomised controlled trial. Lancet Oncol 2009;10:672-682.
41. Kitchener HC, Almonte M, Gilham C, Dowie R, Stoykova B, Sargent A, et al. ARTISTIC: a randomised trial of human papillomavirus (HPV) testing in primary cervical screening. Health Technol Assess 2009;13:1-150, iii-iv.
42. Kitchener HC, Almonte M, Wheeler P, Desai M, Gilham C, Bailey A, et al. HPV testing in routine cervical screening: cross sectional data from the ARTISTIC trial. Br J Cancer 2006;95:56-61.
43. Sargent A, Bailey A, Almonte M, Turner A, Thomson C, Peto J, et al. Prevalence of type-specific HPV infection by age and grade of cervical cytology: data from the ARTISTIC trial. Br J Cancer 2008;98:1704-1709.
44. Jones BA, Novis DA. Follow-up of abnormal gynecologic cytology: a college of American pathologists Q-probes study of 16132 cases from 306 laboratories. Arch Pathol Lab Med 2000;124:665-671.
45. ASCUS-LSIL Triage Study (ALTS) Group. Results of a randomized trial on the management of cytology inter-pretations of atypical squamous cells of undetermined significance. Am J Obstet Gynecol 2003;188:1383-1392.
46. Ferris DG, Wright TCJr, Litaker MS, Richart RM, Lorincz AT, Sun XW, et al. Triage of women with ASCUS and LSIL on Pap smear reports: management by repeat Pap smear, HPV DNA testing, or colposcopy? J Fam Pract 1998;46:125-134.
47. Manos MM, Kinney WK, Hurley LB, Sherman ME, Shieh- Ngai J, Kurman RJ, et al. Identifying women with cervical neoplasia: using human papillomavirus DNA testing for equivocal Papanicolaou results. JAMA 1999;281:1605-1610.
48. Lonky NM, Felix JC, Naidu YM, Wolde-Tsadik G. Triage of atypical squamous cells of undetermined significance with hybrid capture II: colposcopy and histologic human papillomavirus correlation. Obstet Gynecol 2003;101:481-489.
49. Jeronimo J, Khan MJ, Schiffman M, Solomon D. Does the interval between papanicolaou tests influence the quality of cytology? Cancer 2005;105:133-138.
50. Guido R, Schiffman M, Solomon D, Burke L. Postcolpo-scopy management strategies for women referred with low-grade squamous intraepithelial lesions or human papillomavirus DNA-positive atypical squamous cells of undetermined significance: a two-year prospective study. Am J Obstet Gynecol 2003;188:1401-1405.
51. Veljovich DS, Stoler MH, Anderson WA, Covell JL, Rice LW. Atypical glandular cells of undetermined significance: a five-year retrospective histopathologic study. Am J Obstet Gynecol 1998;179:382-390.
52. Sharpless KE, Schnatz PF, Mandavilli S, Greene JF, Soroski JI. Dysplasia associated with atypical glandular cells on cervical cytology. Obstet Gynecol 2005;105:494-500.
53. Derchain SF, Rabelo-Santos SH, Sarian LO, Zeferino LC, de Oliveira Zambeli ER, do Amaral Westin MC, et al. Human papillomavirus DNA detection and histological findings in women referred for atypical glandular cells or adenocarcinoma in situ in their Pap smears. Gynecol Oncol 2004;95:618-623.
54. Mulhem E, Amin M, Copeland J, Sharma J, Hunter S. Type-specific human papillomavirus DNA detected in atypical glandular cell Pap tests. Acta Cytol 2012;56:155-159.
55. Ronnett BM, Manos MM, Ransley JE, Fetterman BJ, Kinney WK, Hurley LB, et al. Atypical glandular cells of undeter-mined significance (AGUS): cytopathologic features, histopathologic results, and human papillomavirus DNA detection. Hum Pathol 1999;30:816-825.
56. Chhieng DC, Elgert P, Cohen JM, Cangiarella JF. Clinical significance of atypical glandular cells of undetermined significance in postmenopausal women. Cancer 2001;93: 1-7.
57. Sharpless KE, Schnatz PF, Mandavilli S, Greene JF, Sorosky JI. Lack of adherence to practice guidelines for women with atypical glandular cells on cervical cytology. Obstet Gynecol 2005;105:501-506.
58. Bao YP, Smith JS, Qiao YL; ACCPAB members. Human papillomavirus type distribution in women from Asia: a meta-analysis. Int J Gynecol Cancer 2008;18:71-79.
59. RD, Wright TC; Optical Detection Group. Effective cervical neoplasia detection with a novel optical detection system: a randomized trial. Gynecol Oncol 2007;104:281-289.
60. ASCUS-LSIL Triage Study (ALTS) Group. A randomized trial on the management of low-grade squamous intraepithelial lesion cytology interpretations. Am J Obstet Gynecol 2003;188:1393-1400.
61. Chute DJ, Covell J, Pambuccian SE, Stelow EB. Cytologic-histologic correlation of screening and diagnostic Papanicolaou tests. Diagn Cytopathol 2006;34:503-506.
62. Lee JK, Kim MK, Song SH, Hong JH, Min KJ, Kim JH, et al. Comparison of human papillomavirus detection and typing by hybrid capture 2, linear array, DNA chip, and cycle sequencing in cervical swab samples. Int J Gynecol Cancer 2009;19:266-272.
63. Numnum TM, Kirby TO, Leath CA III, Huh WK, Alvarez RD, Straughn JMJr. A prospective evaluation of see and treat in women with HSIL Pap smear results: is this an appropriate strategy? J Low Genit Tract Dis 2005;9:2-6.
64. Holschneider CH, Ghosh K, Montz FJ. See-and-treat in the management of high-grade squamous intraepithelial lesions of the cervix: a resource utilization analysis. Obstet Gynecol 1999;94:377-385.
65. Dunn TS, Burke M, Shwayder J. A see and treat management for high-grade squamous intraepithelial lesion pap smears. J Low Genit Tract Dis 2003;7:104-106.
66. Wright TC Jr, Massad LS, Dunton CJ, Spitzer M, Wilkinson EJ, Solomon D. 2006 Consensus guidelines for the management of women with cervical intraepithelial neo-plasia and adenocarcinoma in situ. Am J Obstet Gynecol 2007;197:340-345.
67. International Agency for Research on Cancer (IARC). IARC handbooks of cancer: cervix cancer screening. Vol 10. Lyon: IARC; 2005.
68. Bigras G, de Marval F. The probability for a Pap test to be abnormal is directly proportional to HPV viral load: results from a Swiss study comparing HPV testing and liquid-based cytology to detect cervical cancer precursors in 13,842 women. Br J Cancer 2005;93:575-581.
69. Kulasingam SL, Hughes JP, Kiviat NB, Mao C, Weiss NS, Kuypers JM, et al. Evaluation of human papillomavirus testing in primary screening for cervical abnormalities: comparison of sensitivity, specificity, and frequency of referral. JAMA 2002;288:1749-1757.
70. Mayrand MH, Duarte-Franco E, Coutlee F, Rodrigues I, Walter SD, Ratnam S, et al. Randomized controlled trial of human papillomavirus testing versus Pap cytology in the primary screening for cervical cancer precursors: design, methods and preliminary accrual results of the Canadian cervical cancer screening trial (CCCaST). Int J Cancer 2006;119:615-623.
71. Mayrand MH, Duarte-Franco E, Rodrigues I, Walter SD, Hanley J, Ferenczy A, et al. Human papillomavirus DNA versus Papanicolaou screening tests for cervical cancer. N Engl J Med 2007;357:1579-1588.
72. Cardenas-Turanzas M, Nogueras-Gonzalez GM, Scheurer ME, Adler-Storthz K, Benedet JL, Beck JR, et al. The performance of human papillomavirus high-risk DNA testing in the screening and diagnostic settings. Cancer Epidemiol Biomarkers Prev 2008;17:2865-2871.
73. Petry KU, Menton S, Menton M, de Carvalho Gomes H, Holz B, Schopp B et al. Inclusion of HPV testing in routine cervical cancer screening for women above 29 years in Germany: results for 8466 patients. Br J Cancer 2003;88: 1570-1577.
74. Kjaer S, Hogdall E, Frederiksen K, Munk C, van den Brule A, Svare E, et al. The absolute risk of cervical abnormalities in high-risk human papillomavirus-positive, cytologically normal women over a 10-year period. Cancer Res 2006;66:10630-10636.
75. Khan MJ, Castle PE, Lorincz AT, Wacholder S, Sherman M, Scott DR, et al. The elevated 10-year risk of cervical precancer and cancer in women with human papillomavirus type 16 or 18 and the possible utility of type-specific HPV testing in clinical practice. J Natl Cancer Inst 2005;97:1072-1079.
76. Cho EJ, Do JH, Kim YS, Bae S, Ahn WS. Evaluation of a liquid bead array system for high-risk human papillo-mavirus detection and genotyping in comparison with Hybrid Capture II, DNA chip and sequencing methods. J Med Microbiol 2011;60:162-171.
77. Hong JH, Song SH, Kim JK, Han JH, Lee JK. Comparison of the novel human papillomavirus 4 auto-capillary electrophoresis test with the hybrid capture 2 assay and with the PCR HPV typing set test in the detection of high-risk HPV including HPV 16 and 18 genotypes in cervical specimens. J Korean Med Sci 2009;24:579-584.
78. Song SH, Hong JH, Kwak SH, Lee JK, Kim MK. Clinical performance assessment of five human papillomavirus DNA tests using liquid-based cytology samples. J Obstet Gynaecol Res 2012;38:408-414.
79. Castle PE, Stoler MH, Wright TCJr, Sharma A, Wright TL, Behrens CM. Performance of carcinogenic human papillo-mavirus (HPV) testing and HPV16 or HPV18 genotyping for cervical cancer screening of women aged 25 years and older: a subanalysis of the ATHENA study. Lancet Oncol 2011;12:880-890.
80. Fetterman B, Shaber R, Pawlick G, Kinney WK. Human papillomavirus DNA testing in routine clinical practice for prediction of underlying cervical intraepithelial neoplasia 2/3+ at initial evaluation and in follow-up of women with atypical glandular cell Papanicolaou tests. J Low Genit Tract Dis 2006;10:178-179.
81. Cuzick J, Szarewski A, Cubie H, Hulman G, Kitchener H, Luesley D, et al. Management of women who test positive for high-risk types of human papillomavirus: the HART study. Lancet 2003;362:1871-1876.
82. Clavel C, Masure M, Bory JP, Putaud I, Mangeonjean C, Lorenzato M, et al. Human papillomavirus testing in primary screening for the detection of high-grade cervical lesions: as study of 7932 women. Br J Cancer 2001;84:1616-1623.
83. Wright TCJr, Stoler MH, Behrens CM, Apple R, Derion T, Wright TL. The ATHENA human papillomavirus study: design, methods, and baseline results. Am J Obstet Gynecol 2012;206:46.e1-e46.e11.
84. Kjaer SK, Frederiksen K, Munk C, Iftner T. Long-term absolute risk of cervical intraepithelial neoplasia grade 3 or worse following human papillomavirus infection: role of persistence. J Natl Cancer Inst 2010;102:1478-1488.
85. Winer RL, Lee SK, Hughes JP, Adam DE, Kiviat NB, Koutsky LA. Genital human papillomavirus infection: incidence and risk factors in a cohort of female university students. Am J Epidemiol 2003;157:218-226.
86. Brown DR, Shew ML, Qadadri B, Neptune N, Vargas M, Tu W, et al. A longitudinal study of genital human papillomavirus infection in cohort of closely followed adolescent women. J Infect Dis 2005;191:182-192.
87. Sellors JW, Karwalajtys TL, Kaczorowski J, Mahony JB, Lytwyn A, Chong S, et al. Incidence, clearance and predictors of human papillomavirus infection in women. CMAJ 2003;168:421-425.
88. Ho GY, Bierman R, Beardsley L, Chang CJ, Burk RD. Natural history of cervicovaginal papillomavirus infection in young women. N Engl J Med 1998;338:423-428.
89. Wetta LA, Matthews KS, Kemper ML, Whitworth JM, Fain ET, Huh WK, et al. The management of cervical intraepithelial neoplasia during pregnancy: is colposcopy necessary? J Low Genit Tract Dis 2009;13:182-185.
90. Fader AN, Alward EK, Niederhauser A, Chirico C, Lesnock JL, Zwiesler DJ, et al. Cervical dysplasia in pregnancy: a multi-institutional evaluation. Am J Obstet Gynecol 2010;203:113.e1-e113.e6.
91. Vlahos G, Rodolakis A, Diakomanolis E, Stefanidis K, Haidopoulos D, Abela K, et al. Conservative management of cervical intraepithelial neoplasia (CIN(2-3)) in pregnant women. Gynecol Obstet Invest 2002;54:78-81.
92. Serati M, Uccella S, Laterza RM, Salvatore S, Beretta P, Riva C, et al. Natural history of cervical intraepithelial neoplasia during pregnancy. Acta Obstet Gynecol Scand 2008;87:1296-1300.
93. Kreimer AR, Guido RS, Solomon D, Schiffman M, Wacholder S, Jeronimo J, et al. Human papillomavirus testing following loop electrosurgical excision procedure identifies women at risk for posttreatment cervical intraepithelial neoplasia grade 2 or 3 disease. Cancer Epidemiol Biomarkers Prev 2006;15:908-914.